Sabby Management LLC lessened its position in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 47.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,000 shares of the biotechnology company’s stock after selling 43,500 shares during the quarter. Sabby Management LLC owned 0.47% of Eiger Biopharmaceuticals worth $684,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its position in Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 8,748 shares during the period. OxFORD Asset Management LLP purchased a new stake in Eiger Biopharmaceuticals during the third quarter valued at about $147,000. Unterberg Capital LLC purchased a new stake in Eiger Biopharmaceuticals during the fourth quarter valued at about $698,000. Renaissance Technologies LLC boosted its position in Eiger Biopharmaceuticals by 22.8% during the fourth quarter. Renaissance Technologies LLC now owns 97,013 shares of the biotechnology company’s stock valued at $1,353,000 after buying an additional 18,000 shares during the period. Finally, P.A.W. Capital Corp boosted its position in Eiger Biopharmaceuticals by 25.0% during the fourth quarter. P.A.W. Capital Corp now owns 100,000 shares of the biotechnology company’s stock valued at $1,395,000 after buying an additional 20,000 shares during the period. 68.96% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have issued reports on the stock. Zacks Investment Research lowered shares of Eiger Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th. Oppenheimer set a $26.00 price target on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 12th. ValuEngine lowered shares of Eiger Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Piper Jaffray Companies reiterated an “overweight” rating and set a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 target price for the company. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $27.25.
Shares of Eiger Biopharmaceuticals Inc (EIGR) opened at $9.50 on Tuesday. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.58. Eiger Biopharmaceuticals Inc has a 1-year low of $6.10 and a 1-year high of $16.20. The company has a market cap of $96.85, a PE ratio of -1.95 and a beta of 1.70.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.02) by ($0.09). equities analysts anticipate that Eiger Biopharmaceuticals Inc will post -4.48 EPS for the current fiscal year.
WARNING: “Eiger Biopharmaceuticals Inc (EIGR) Shares Sold by Sabby Management LLC” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/03/20/eiger-biopharmaceuticals-inc-eigr-shares-sold-by-sabby-management-llc.html.
Eiger Biopharmaceuticals Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.